Clinical Trial Update: Phase IIa Clinical Study of N-Rephasin® SAL200 [Phase 2]

View source ↗

Summary

Phase IIa trial of N-Rephasin SAL200 was terminated; results posted in 2021 for Staphylococcus aureus bacteremia treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Bacteremia

Drugs mentioned

• N-Rephasin SAL200 (N-Rephasin SAL200)

Snippet

Sponsor: Intron Biotechnology, Inc. | Conditions: Staphylococcus Aureus Bacteremia, Anti-Bacterial Agents | Phase 2 | Status: TERMINATED | Results posted: 2021-08-17